This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the United Nations Environment Programme, the International Labour Organisation, or the World Health Organization.

Environmental Health Criteria 80

PYRROLIZIDINE ALKALOIDS

Published under the joint sponsorship of the United Nations Environment Programme, the International Labour Organisation, and the World Health Organization.

World Health Organization
Geneva, 1988
CONTENTS

ENVIRONMENTAL HEALTH CRITERIA FOR PYRROLIZIDINE ALKALOIDS

PREFACE .................................. 12
INTRODUCTION - PYRROLIZIDINE ALKALOIDS AND HUMAN HEALTH .... 13

1. SUMMARY AND RECOMMENDATIONS .................................. 19
   1.1 Summary ............................................. 19
   1.2 Sources and chemical structure ........................... 19
   1.3 Mechanisms and features of toxicity ...................... 20
   1.4 Effects on man ........................................ 22
      1.4.1 Nature and extent of health risks .............. 22
   1.5 Methods for prevention ................................ 24
   1.6 Recommendations ....................................... 24
      1.6.1 General recommendations ......................... 24
      1.6.2 Recommendations for research ................... 25

2. PROPERTIES AND ANALYTICAL METHODS ............................. 27
   2.1 Chemical structure and properties ....................... 27
   2.2 Analytical methods .................................... 32
      2.2.1 Extraction ....................................... 33
         2.2.1.1 Plant tissue ................................... 33
         2.2.1.2 Biological fluids and tissues ............... 33
      2.2.2 Analysis for pyrrolizidine alkaloids ............. 33
         2.2.2.1 Thin-layer chromatography (TLC) ........... 33
         2.2.2.2 High-performance liquid chromatography (HPLC) 34
         2.2.2.3 Gas chromatography (GC) and mass spectrometry (MS) 34
         2.2.2.4 Nuclear magnetic resonance (NMR) spectrometry 35
         2.2.2.5 The Ehrlich reaction .......................... 35
         2.2.2.6 Indicator dyes .................................. 36
         2.2.2.7 Direct weighing ................................ 36
   2.3 Determination of metabolites in animal tissues ......... 37

3. SOURCES AND PATHWAYS OF EXPOSURE ............................. 38
   3.1 Hepatotoxic pyrrolizidine alkaloids and their sources .... 38
   3.2 Pneumotoxic and other toxic pyrrolizidine alkaloids .... 40
3.3 Pathways of exposure

3.3.1 Contamination of staple food crops
3.3.2 Herbal infusions
3.3.3 Use of PA-containing plants as food
3.3.4 Contaminated honey
3.3.5 Milk
3.3.6 Meat
3.3.7 Use of PAs as chemotherapeutic agents for cancer

4. METABOLISM

4.1 Absorption, excretion, and tissue distribution
4.1.1 Absorption
4.1.2 Excretion and distribution
4.2 Metabolic routes
4.2.1 Hydrolysis
4.2.2 N-oxidation
4.2.3 Conversion to pyrrolic metabolites
4.3 Effects of treatments affecting metabolism
4.4 Other factors affecting metabolism
4.5 Other metabolic routes
4.6 Metabolism of pyrrolizidine N-oxides
4.7 Metabolism in man

5. MECHANISMS OF TOXICITY AND OTHER BIOLOGICAL ACTIONS

5.1 Metabolites responsible for toxicity
5.1.1 Metabolic basis of toxicity
5.1.2 Isolation of pyrrolic metabolites
5.1.3 Chemical aspects of pyrrolic metabolites
5.1.3.1 Preparation
5.1.3.2 Chemistry associated with toxic actions
5.1.4 Possible further metabolites
5.2 Toxic actions of pyrrolic metabolites
5.2.1 Animals
5.2.1.1 Pyrrolic esters (dehydro-alkaloids)
5.2.1.2 Pyrrolic alcohols (dehydro-necines)
5.2.2 Cell cultures
5.2.3 Possible participation of membrane lipid peroxidation
5.3 Chemical and metabolic factors affecting toxicity
5.3.1 Structural features of a toxic alkaloid
5.3.2 Activation and detoxication .......................... 73
5.3.3 Factors affecting the toxicity of active metabolites .......................... 74
  5.3.3.1 Reactivity of the metabolite ........................................ 74
  5.3.3.2 The number of reactive groups ....................................... 74
5.4 Metabolites associated with the biological actions of pyrrolizidine alkaloids .......................... 75
  5.4.1 Acute hepatotoxicity .................................................. 75
  5.4.2 Chronic hepatotoxicity ................................................ 75
  5.4.3 Pneumotoxicity ......................................................... 76
  5.4.4 Toxicity in other tissues .............................................. 76
  5.4.5 Carcinogenicity ....................................................... 77
  5.4.6 Antitumour activity ................................................... 77
5.5 Prevention and treatment of pyrrolizidine poisoning ......................................................... 78
  5.5.1 Modified diets .......................................................... 78
  5.5.2 Pre-treatment to enhance the detoxication of active metabolites .......................... 79
  5.5.3 Other treatments ...................................................... 80
6. EFFECTS ON ANIMALS ................................................. 81
  6.1 Patterns of disease caused by different plant genera and of organ involvement in different species ......................................................... 81
  6.2 Field observations - outbreaks in farm animals ......................................................... 81
  6.3 Studies on farm animals ................................................ 84
  6.4 Experimental animal studies ............................................ 87
    6.4.1 Effects on the liver .................................................. 87
      6.4.1.1 Relative hepatotoxicity of different PAs and their N-oxides ......................................................... 87
      6.4.1.2 Factors affecting hepatotoxicity .................................. 87
      6.4.1.3 Acute effects ........................................................ 92
      6.4.1.4 Mechanism of toxic action ........................................ 97
      6.4.1.5 Chronic effects .................................................... 98
    6.4.2 Effects on the lungs .................................................. 103
      6.4.2.1 Acute effects ........................................................ 105
      6.4.2.2 Chronic effects .................................................... 110
      6.4.2.3 Mechanisms of toxic action ........................................ 114
    6.4.3 Effects on the central nervous system .................................. 121
    6.4.4 Effects on other organs .............................................. 121
    6.4.5 Teratogenicity ....................................................... 124
    6.4.6 Fetotoxicity ......................................................... 124
    6.4.7 Mutagenicity .......................................................... 126
      6.4.7.1 Chromosome damage ................................................ 129
    6.4.8 Carcinogenesis ....................................................... 131
      6.4.8.1 Purified alkaloids ................................................ 162
6.4.8.2 Plant materials ........................................ 167
6.4.8.3 Pyrrolizidine alkaloid metabolites
and analogous synthetic
compounds ........................................ 171
6.4.8.4 Molecular structure and
 carcinogenic activity .................................. 173
6.4.9 Antimitotic activity ........................................ 174
6.4.10 Immunosuppression ....................................... 175
6.4.11 Effects on mineral metabolism .......................... 175
6.4.12 Methods for the assessment of chronic
 hepatotoxicity and pneumotoxicity ..................... 176
6.5 Effects on wild-life ......................................... 177
6.5.1 Deer ........................................ 177
6.5.2 Fish ........................................ 177
6.5.3 Insects ........................................ 178

7. EFFECTS ON MAN .............................................. 179

7.1 Clinical features of veno-occlusive disease
(VOD) ..................................................... 179
7.2 Salient pathological features of veno-
oclusive disease ......................................... 181
7.3 Human case reports of veno-occlusive disease ..... 183
7.4 VOD and cirrhosis of the liver ........................... 201
7.5 Differences between VOD and
 Indian childhood cirrhosis (ICC) ....................... 203
7.6 Chronic lung disease ...................................... 204
7.7 Trichodesma poisoning ..................................... 205
7.8 Relationship between dose level and toxic
effects .................................................... 206
7.9 Pyrrolizidine alkaloids as a chemotherapeutic
agent for cancer ......................................... 213
7.10 Prevention of poisoning in man ....................... 214

8. BIOLOGICAL CONTROL ........................................ 216

9. EVALUATION OF HUMAN HEALTH RISKS AND EFFECTS
ON THE ENVIRONMENT ....................................... 217

9.1 Human exposure conditions ............................... 217
9.1.1 Reported sources of human exposure .......... 217
9.1.2 Plant species involved .............................. 217
9.1.3 Modes and pathways of exposure ................ 218
 9.1.3.1 Contamination of grain crops .......... 218
 9.1.3.2 Herbal medicines .......................... 218
 9.1.3.3 PA-containing plants used as food
     and beverages .................................. 219
 9.1.3.4 Other food contaminated by PAs ........ 219
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.1.4 Levels of intake</td>
<td>220</td>
</tr>
<tr>
<td>9.2 Acute effects of exposure</td>
<td>222</td>
</tr>
<tr>
<td>9.2.1 Acute liver disease</td>
<td>222</td>
</tr>
<tr>
<td>9.3 Chronic effects of exposure</td>
<td>223</td>
</tr>
<tr>
<td>9.3.1 Cirrhosis of the liver</td>
<td>223</td>
</tr>
<tr>
<td>9.3.2 Mutagenicity and teratogenicity</td>
<td>223</td>
</tr>
<tr>
<td>9.3.3 Cancer of the liver</td>
<td>223</td>
</tr>
<tr>
<td>9.3.4 Effects on other organs</td>
<td>224</td>
</tr>
<tr>
<td>9.4 Effects on the environment</td>
<td>225</td>
</tr>
<tr>
<td>9.4.1 Agriculture</td>
<td>225</td>
</tr>
<tr>
<td>9.4.2 Wild-life</td>
<td>226</td>
</tr>
<tr>
<td>9.4.3 Insects</td>
<td>226</td>
</tr>
<tr>
<td>9.4.4 Soil and water</td>
<td>226</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>227</td>
</tr>
<tr>
<td>APPENDIX I. PYRROLIZIDINE ALKALOIDS AND THEIR PLANT SOURCES</td>
<td>275</td>
</tr>
<tr>
<td>APPENDIX II.</td>
<td></td>
</tr>
<tr>
<td>TABLE 1. PLANTS CONTAINING HEPATOTOXIC PYRROLIZIDINE ALKALOIDS</td>
<td>303</td>
</tr>
<tr>
<td>TABLE 2. PLANTS CONTAINING KNOWN ALKALOIDS THAT ARE NON-HEPATOTOXIC (AMINOALCOHOLS AND ESTERS)</td>
<td>337</td>
</tr>
</tbody>
</table>